Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | 2026-10-15 14:06:26 | 19.62 | 0.35 | 1.82 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACAD | 0001070494 | ACADIA PHARMACEUTICALS INC | US0042251084 | 529900O3044NO0PEA039 | 061376651 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 12830 EL CAMINO REAL | SAN DIEGO | CA | 92130 | UNITED STATES | US | 858-558-2871 | 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130 | 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130 | — | Biopharmaceutical | 1993 | Stephen R. Davis | 570 | http://acadia.com | 2,300,000,000 | 172,132,442 | 172,305,518 | Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California. | 2026-10-09 02:01:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 2,300,000,000 | 300,000,000 | 15 | 170,494,613 | 3,706,096 | 2.222 |
| 2024 | 2,000,000,000 | -900,000,000 | -31.0345 | 166,788,517 | 2,016,996 | 1.2241 |
| 2023 | 2,900,000,000 | 1,200,000,000 | 70.5882 | 164,771,521 | 2,541,337 | 1.5665 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 798 |
| 2024 | 654 |
| 2023 | 598 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 1,071,505,000 | 957,797,000 | 726,437,000 |
| Cost Of Revenue | 88,998,000 | 81,841,000 | 41,638,000 |
| Gross Profit | 982,507,000 | 875,956,000 | 684,799,000 |
| Research And Development Expenses | 328,802,000 | 303,249,000 | 351,619,000 |
| General And Administrative Expenses | 548,894,000 | 488,428,000 | 406,559,000 |
| Operating Expenses | 966,694,000 | 727,003,000 | 799,816,000 |
| Operating Income | 104,811,000 | 230,794,000 | -73,379,000 |
| Net Income | 391,000,000 | 226,451,000 | -61,286,000 |
| Earnings Per Share Basic | 2.32 | 1.37 | -0.37 |
| Earnings Per Share Diluted | 2.3 | 1.36 | -0.37 |
| Weighted Average Shares Outstanding Basic | 168,356,000 | 165,717,000 | 163,819,000 |
| Weighted Average Shares Outstanding Diluted | 169,919,000 | 166,362,000 | 163,819,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 177,695,000 | 319,589,000 | 188,657,000 |
| Marketable Securities Current | 641,991,000 | 436,404,000 | 250,208,000 |
| Accounts Receivable | 121,457,000 | 98,739,000 | 98,267,000 |
| Inventories | 111,374,000 | 91,690,000 | 40,447,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 59,526,000 | 55,681,000 | 39,091,000 |
| Total Assets Current | 1,062,113,000 | 938,318,000 | 616,125,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 7,511,000 | 4,215,000 | 4,612,000 |
| Other Assets Non Current | 3,896,000 | 359,000 | 476,000 |
| Total Assets Non Current | 502,082,000 | 249,438,000 | 132,831,000 |
| Total Assets | 1,564,195,000 | 1,187,756,000 | 748,956,000 |
| Accounts Payable | 10,903,000 | 16,192,000 | 17,543,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 266,211,000 | 378,678,000 | 236,711,000 |
| Total Liabilities Current | 277,114,000 | 394,870,000 | 254,254,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 19,137,000 | 18,056,000 | 15,147,000 |
| Total Liabilities Non Current | 59,691,000 | 60,093,000 | 62,947,000 |
| Total Liabilities | 336,805,000 | 454,963,000 | 317,201,000 |
| Common Stock | 16,000 | 16,000 | 16,000 |
| Retained Earnings | -1,813,386,000 | -2,204,386,000 | -2,430,837,000 |
| Accumulated Other Comprehensive Income | 1,445,000 | 292,000 | 24,000 |
| Total Shareholders Equity | 1,227,390,000 | 732,793,000 | 431,755,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 871,000 | 920,000 | 1,459,000 |
| Share Based Compensation Expense | 52,135,000 | 67,049,000 | 66,421,000 |
| Other Non Cash Income Expense | 0 | 146,515,000 | — |
| Change In Accounts Receivable | 22,718,000 | 472,000 | 36,072,000 |
| Change In Inventories | 18,197,000 | 49,550,000 | 28,808,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 2,856,000 | -117,000 | 33,000 |
| Change In Accounts Payable | -5,289,000 | -1,351,000 | 4,797,000 |
| Change In Other Liabilities | 1,081,000 | 2,909,000 | 6,073,000 |
| Cash From Operating Activities | 109,836,000 | 157,719,000 | 16,702,000 |
| Purchases Of Marketable Securities | 692,565,000 | 505,095,000 | 369,985,000 |
| Sales Of Marketable Securities | 493,529,000 | 328,565,000 | 429,780,000 |
| Acquisition Of Property Plant And Equipment | 4,690,000 | 523,000 | 50,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -302,564,000 | -30,538,000 | 31,998,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 49,883,000 | 6,845,000 | 25,129,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 49,883,000 | 6,845,000 | 25,129,000 |
| Change In Cash | -142,819,000 | 133,932,000 | 73,811,000 |
| Cash At End Of Period | 177,695,000 | 319,589,000 | 188,657,000 |
| Income Taxes Paid | 24,039,000 | 19,521,000 | 5,850,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 2.32 | 1.37 | -0.37 |
| Price To Earnings Ratio | 11.5129 | 13.3942 | -84.6216 |
| Earnings Growth Rate | 69.3431 | -470.2703 | -72.3881 |
| Price Earnings To Growth Ratio | 0.166 | -0.0285 | 1.169 |
| Book Value Per Share | 7.2904 | 4.422 | 2.6356 |
| Price To Book Ratio | 3.6637 | 4.1497 | 11.8798 |
| Ebitda | 415,910,000 | 246,892,000 | -53,977,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 4,167,000 | 523,000 | 50,000 |
| Free Cash Flow | 105,669,000 | 157,196,000 | 16,652,000 |
| Return On Equity | 0.3186 | 0.309 | -0.1419 |
| One Year Beta | 0.8793 | 0.7986 | 1.2241 |
| Three Year Beta | 0.9425 | 1.0593 | 0.949 |
| Five Year Beta | 0.9126 | 0.875 | 0.9047 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2026-08-06 | 14,292 | A | 82,120 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2026-08-06 | 5,000 | D | 77,120 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2026-08-06 | 9,292 | D | 67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2026-08-06 | 14,292 | D | 60,423 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 2026-08-05 | 5,849 | A | 73,677 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Christopher L. Jacobs | 2022-07-28 | NY27 | Sale | 2022-06-16 | — | $1,001 - $15,000 |
| Christopher L. Jacobs | 2020-11-06 | NY27 | Sale (Partial) | 2020-09-08 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2019-03-08 | CA39 | Sale | 2019-02-19 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| State of Alaska, Department of Revenue | 2026-09-30 | 1,114,000 | 55,345 | 20.1283 |
| Assenagon Asset Management S.A. | 2026-09-30 | 6,741,303 | 334,556 | 20.15 |
| MARYLAND CAPITAL ADVISORS INC. | 2026-09-30 | 21 | 1 | 21 |
| Cedar Mountain Advisors, LLC | 2026-09-30 | 6,206 | 308 | 20.1494 |
| Atria Investments, Inc | 2026-09-30 | 258,101 | 12,809 | 20.15 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 1,841 | 47,626.67 | 0.1979 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech ETF | BBP | 64,350 | 1,664,734.5 | 1.6893 |
| PRUDENTIAL WORLD FUND, INC. | 2026-07-31 | Class R6 | PJRQX | 69,783 | 731,379.66 | 0.1653 |
| PRUDENTIAL WORLD FUND, INC. | 2026-07-31 | Class Z | PJIZX | 69,783 | 731,379.66 | 0.1653 |
| PRUDENTIAL WORLD FUND, INC. | 2026-07-31 | Class C | PJRCX | 69,783 | 731,379.66 | 0.1653 |